High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

NCT02203604 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Insufficient rate of accrual

Conditions

Recurrent Melanoma
Stage IIIA Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma
Stage IV Melanoma

Interventions

BIOLOGICAL: aldesleukin
BIOLOGICAL: ipilimumab
OTHER: laboratory biomarker analysis

Sponsor

CINJRegulatory

Collaborators

[object Object]
[object Object]